Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924208 | 0.79 | CRHR1 (0.46) | ALDH1A1HPGDCRHR1KMT2A | |
| SCHEMBL2258421 | 0.75 | CRHR1 (0.38) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL2255140 | 0.75 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL2256730 | 0.75 | MAPT (0.48) | ALDH1A1KDM4EHPGDMAPTCRHR1 | |
| SCHEMBL2259585 | 0.74 | MAPT (0.31) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2252782 | 0.70 | CRHR1 (0.47) | ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPT | |
| SCHEMBL1922416 | 0.67 | HSD11B1 (0.41) | ALDH1A1HPGDCRHR1KMT2A | |
| SCHEMBL1924190 | 0.65 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL2255193 | 0.65 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL2255756 | 0.64 | CRHR1 (0.43) | ALDH1A1HPGDCRHR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035874-A1 | Organic compounds | CRH, CRHR1, CRHR2 | ALDH1A1 1728/4885KDM4E 4367/4885HPGD 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.